AU586286B2 - Pharmaceutical and dietary composition - Google Patents

Pharmaceutical and dietary composition

Info

Publication number
AU586286B2
AU586286B2 AU63407/86A AU6340786A AU586286B2 AU 586286 B2 AU586286 B2 AU 586286B2 AU 63407/86 A AU63407/86 A AU 63407/86A AU 6340786 A AU6340786 A AU 6340786A AU 586286 B2 AU586286 B2 AU 586286B2
Authority
AU
Australia
Prior art keywords
complications
pharmaceutical
metabolites
gamma
linolenic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63407/86A
Other languages
English (en)
Other versions
AU6340786A (en
Inventor
Hugh Carmichael
David Frederick Horrobin
Goran A. Jamal
Charles Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Efamol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Ltd filed Critical Efamol Ltd
Publication of AU6340786A publication Critical patent/AU6340786A/en
Application granted granted Critical
Publication of AU586286B2 publication Critical patent/AU586286B2/en
Assigned to SCOTIA HOLDINGS PLC reassignment SCOTIA HOLDINGS PLC Alteration of Name(s) in Register under S187 Assignors: EFAMOL LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU63407/86A 1985-10-02 1986-09-30 Pharmaceutical and dietary composition Ceased AU586286B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8524275 1985-10-02
GB858524275A GB8524275D0 (en) 1985-10-02 1985-10-02 Pharmaceutical & dietary compositions

Publications (2)

Publication Number Publication Date
AU6340786A AU6340786A (en) 1987-04-09
AU586286B2 true AU586286B2 (en) 1989-07-06

Family

ID=10586062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63407/86A Ceased AU586286B2 (en) 1985-10-02 1986-09-30 Pharmaceutical and dietary composition

Country Status (14)

Country Link
US (1) US4826877A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0218460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6296421A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE84414T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU586286B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1279824C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3687501T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2043601T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8524275D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3007043T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK129393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE59445B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG115193G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA867386B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601238B2 (en) * 1986-11-13 1990-09-06 Efamol Holdings Plc A method of treatment of pregnancy induced hypertension
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
EP1092352A3 (en) * 1991-01-24 2003-08-27 Martek Corporation Microbial oil mixtures and uses thereof
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
ES2218525T3 (es) * 1993-06-09 2004-11-16 Martek Biosciences Corporation Metodo y preparaciones farmaceuticas para el tratamiento de trastornos neurologicos.
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
IT1265340B1 (it) * 1993-07-14 1996-11-22 Istituto Biochimico Italiano Sostanze inibenti l'adp-ribosilazione proteica atte alla prevenzione delle complicanze del diabete mellito.
EP0734723A4 (en) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
GB9412925D0 (en) * 1994-06-28 1994-08-17 Scotia Holdings Plc Combination of aldose reductase inhibitors with gamma-linolenic (GLA) dihomogammalinolenic (DGLA) or arachidonic (AA) acids in the treatment of diabetic
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
IL125731A (en) 1998-08-11 2004-06-20 Zvi Yehuda Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals
US20030163845A1 (en) * 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
US6677145B2 (en) 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
DE19903095C2 (de) * 1999-01-27 2003-05-22 Nutrinova Gmbh Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US7070970B2 (en) 1999-08-23 2006-07-04 Abbott Laboratories Elongase genes and uses thereof
AU784123B2 (en) * 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
CA2301158A1 (en) * 2000-03-24 2001-09-24 Stephen J. Allen Screening methods for compounds useful for modulating lipid metabolism in disease
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US6635451B2 (en) * 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
US7045683B2 (en) * 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
EE200300599A (et) * 2001-05-30 2004-02-16 Laxdale Limited Koensüüm Q ja EPA või muu asendamatu rasvhape
US7211656B2 (en) * 2002-01-30 2007-05-01 Abbott Laboratories Desaturase genes, enzymes encoded thereby, and uses thereof
MXPA04011613A (es) 2002-05-22 2005-03-07 Monsanto Technology Llc Desaturasas de acido graso de hongos.
US7214491B2 (en) * 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7238482B2 (en) 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
FI20060154A7 (fi) * 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
FR2860720A1 (fr) * 2003-10-09 2005-04-15 Jean Pascal Conduzorgues Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires
US7659120B2 (en) 2003-11-12 2010-02-09 E. I. Du Pont De Nemours And Company Δ 15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
EP2902021B1 (en) 2004-04-16 2018-11-14 Monsanto Technology LLC Expression of fatty acid desaturases in corn
KR20070040381A (ko) * 2004-07-01 2007-04-16 셰펜스 아이 리써치 눈의 장애 및 상태를 치료하는 조성물 및 방법
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US7138391B2 (en) * 2004-08-09 2006-11-21 Silverbrook Research Pty Ltd Hydrophilizable and hydrophilic cyanine dyes
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
PT1967198E (pt) * 2007-03-07 2009-06-15 Indena Spa Formulações contendo extractos de cynara scolymus e phaseolus vulgaris úteis no tratamento da obesidade
CN102239254B (zh) 2008-10-06 2014-02-26 雅培制药有限公司 △-8去饱和酶基因、由其编码的酶及其用途
BRPI0915247A2 (pt) * 2008-11-14 2016-02-16 Bomi P Framroze método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética"
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2953633A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4355179A (en) * 1978-01-23 1979-08-02 Efamol Limited Pharmaceutical and dietary compositions
AU1308483A (en) * 1982-04-16 1983-10-20 Societe Des Produits Nestle S.A. Edible lipid composition
AU3766885A (en) * 1984-01-16 1985-07-25 P. F. Medicament Branched c10 to c20 fatty acids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
ATE22532T1 (de) * 1982-03-01 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
US4472432A (en) * 1982-05-12 1984-09-18 Inabata & Co., Ltd. Medicinal use of α,β-unsaturated fatty acids
IL69782A (en) * 1982-09-22 1987-12-20 Sentrachem Ltd Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4355179A (en) * 1978-01-23 1979-08-02 Efamol Limited Pharmaceutical and dietary compositions
AU1308483A (en) * 1982-04-16 1983-10-20 Societe Des Produits Nestle S.A. Edible lipid composition
AU3766885A (en) * 1984-01-16 1985-07-25 P. F. Medicament Branched c10 to c20 fatty acids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy

Also Published As

Publication number Publication date
DE3687501D1 (de) 1993-02-25
CA1279824C (en) 1991-02-05
IE862543L (en) 1987-04-02
EP0218460B1 (en) 1993-01-13
ES2043601T3 (es) 1994-01-01
SG115193G (en) 1994-01-21
ATE84414T1 (de) 1993-01-15
IE59445B1 (en) 1994-02-23
HK129393A (en) 1993-12-03
JPS6296421A (ja) 1987-05-02
EP0218460A2 (en) 1987-04-15
AU6340786A (en) 1987-04-09
GR3007043T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-30
GB8524275D0 (en) 1985-11-06
US4826877A (en) 1989-05-02
ZA867386B (en) 1987-10-28
DE3687501T2 (de) 1993-05-19
EP0218460A3 (en) 1989-08-09

Similar Documents

Publication Publication Date Title
AU586286B2 (en) Pharmaceutical and dietary composition
AU586892B2 (en) Pharmaceutical and dietary composition
PH24867A (en) A method of treating conditions associated with photodamaged skin by using pharmaceutical compositions containing p(22-(5,6,7,8 tetrahydro-5,5,8,8-tetramethyl-2-naphtyl)propenyl)phenylsulfone and derivatives thereof
BG60261B2 (en) Lon-acting formulation of cefaclor
AU8163394A (en) Treatment of diabetes by administration of myo-inositol
EP0334507A3 (en) Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid
AU4936890A (en) Medicament containing dihydrolipoic acid as active substance
EP0548794A3 (en) Polyaspartamide derivative as adsorbent for bile acids, polyaspartamide loaded with bile acids and preparation and use as a drug
AU4538489A (en) Pharmaceutical compositions
AU7018187A (en) Iron - containing composition and method for treatment of cancer
AU563273B2 (en) Composition containing an essential fatty acid and niacin and/or a bile salt binder
AU5911590A (en) Pharmaceutical and dietary uses of fatty acids
AU1176688A (en) Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives
AU4734993A (en) Nutrient or medicinal compositions for administration to ruminants
CA2067374A1 (en) Osteogenesis promoter
AU587625B2 (en) Pharmaceutical and dietary composition
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
AU2063388A (en) Preparation for preventing or combating complications in diabetes